Literature DB >> 9687401

Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.

C M Bébéar1, A Charron, J M Bové, C Bébéar, J Renaudin.   

Abstract

The topoisomerase IV parC and parE genes from the wall-less organism Mycoplasma hominis PG21 were cloned and sequenced. The coupled genes are located far from the DNA gyrase genes gyrA and gyrB. They encode proteins of 639 and 866 amino acids, respectively. As expected, the encoded ParE and ParC proteins exhibit higher homologies with the topoisomerase IV subunits of the gram-positive bacteria Staphylococcus aureus and Streptococcus pneumoniae than with their Escherichia coli counterparts. The conserved regions include the Tyr residue of the active site and the region involved in quinolone resistance (quinolone resistance-determining region [QRDR]) in ParC and the ATP-binding site and the QRDR in ParE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687401      PMCID: PMC105727     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

2.  Cloning and sequencing of the Escherichia coli gyrA gene coding for the A subunit of DNA gyrase.

Authors:  S L Swanberg; J C Wang
Journal:  J Mol Biol       Date:  1987-10-20       Impact factor: 5.469

3.  DNA sequence of the E. coli gyrB gene: application of a new sequencing strategy.

Authors:  T Adachi; M Mizuuchi; E A Robinson; E Appella; M H O'Dea; M Gellert; K Mizuuchi
Journal:  Nucleic Acids Res       Date:  1987-01-26       Impact factor: 16.971

4.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

5.  Structure and function of the region of the replication origin of the Bacillus subtilis chromosome. III. Nucleotide sequence of some 10,000 base pairs in the origin region.

Authors:  S Moriya; N Ogasawara; H Yoshikawa
Journal:  Nucleic Acids Res       Date:  1985-04-11       Impact factor: 16.971

6.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.

Authors:  M E Cullen; A W Wyke; R Kuroda; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  An unusual gene containing a dnaJ N-terminal box flanks the putative origin of replication of Mycoplasma genitalium.

Authors:  C C Bailey; K F Bott
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

9.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

10.  UGA is read as tryptophan in Mycoplasma capricolum.

Authors:  F Yamao; A Muto; Y Kawauchi; M Iwami; S Iwagami; Y Azumi; S Osawa
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

View more
  9 in total

1.  Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.

Authors:  A K Reinhardt; C M Bébéar; M Kobisch; I Kempf; A V Gautier-Bouchardon
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.

Authors:  C M Bébéar; O Grau; A Charron; H Renaudin; D Gruson; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Diagnosis of quinolone-resistant Coxiella burnetii strains by PCR-RFLP.

Authors:  I Spyridaki; A Psaroulaki; A Aransay; E Scoulica; Y Tselentis
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.

Authors:  G E Kenny; P A Young; F D Cartwright; K E Sjöström; W M Huang
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors:  C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

6.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Association of mutation patterns in GyrA and ParC genes with quinolone resistance levels in lactic acid bacteria.

Authors:  Shaoying Li; Zhen Li; Wan Wei; Chunyan Ma; Xiaomin Song; Shufen Li; Wenying He; Jianjun Tian; Xiaoyan Huo
Journal:  J Antibiot (Tokyo)       Date:  2014-09-10       Impact factor: 2.649

8.  Functional analysis of three topoisomerases that regulate DNA supercoiling levels in Chlamydia.

Authors:  Emilie Orillard; Ming Tan
Journal:  Mol Microbiol       Date:  2015-11-13       Impact factor: 3.501

9.  Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen.

Authors:  Stephen H Gillespie; Clare L Ling; Katarina Oravcova; Miguel Pinheiro; Louise Wells; Josephine M Bryant; Timothy D McHugh; Cecile Bébéar; David Webster; Simon R Harris; Helena M B Seth-Smith; Nicholas R Thomson
Journal:  Clin Infect Dis       Date:  2014-10-23       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.